These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

970 related items for PubMed ID: 15973789

  • 1. Authority for practitioners to dispense or prescribe approved narcotic controlled substances for maintenance or detoxification treatment. Final rule.
    Drug Enforcement Administration (DEA), Justice.
    Fed Regist; 2005 Jun 23; 70(120):36338-44. PubMed ID: 15973789
    [Abstract] [Full Text] [Related]

  • 2. Changes to patient limitation for dispensing or prescribing approved narcotic controlled substances for maintenance or detoxification treatment by qualified individual practitioners. Final rule.
    Drug Enforcement Administration (DEA), Justice.
    Fed Regist; 2008 May 22; 73(100):29685-8. PubMed ID: 18605404
    [Abstract] [Full Text] [Related]

  • 3. Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2002 Oct 07; 67(194):62354-70. PubMed ID: 12369590
    [Abstract] [Full Text] [Related]

  • 4. Using buprenorphine for outpatient opioid detoxification.
    Manlandro JJ.
    J Am Osteopath Assoc; 2007 Sep 07; 107(9 Suppl 5):ES11-6. PubMed ID: 17908825
    [Abstract] [Full Text] [Related]

  • 5. Implementation of the Provision of the Comprehensive Addiction and Recovery Act of 2016 Relating to the Dispensing of Narcotic Drugs for Opioid Use Disorder. Final rule.
    Drug Enforcement Administration, Department of Justice..
    Fed Regist; 2018 Jan 23; 83(15):3071-5. PubMed ID: 29359892
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Opioid drugs in maintenance and detoxification treatment of opiate addiction; proposed modification of dispensing restrictions for buprenorphine and buprenorphine combination as used in approved opioid treatment medications. Final rule.
    Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services (HHS).
    Fed Regist; 2012 Dec 06; 77(235):72752-61. PubMed ID: 23227572
    [Abstract] [Full Text] [Related]

  • 8. Dispensing of controlled substances to assist suicide. Interpretive rule.
    Department of Justice.
    Fed Regist; 2001 Nov 09; 66(218):56607-8. PubMed ID: 11760766
    [Abstract] [Full Text] [Related]

  • 9. Buprenorphine for office-based treatment of patients with opioid addiction.
    Manlandro JJ.
    J Am Osteopath Assoc; 2005 Jun 09; 105(6 Suppl 3):S8-13. PubMed ID: 16118361
    [Abstract] [Full Text] [Related]

  • 10. Designation of oripavine as a basic class of controlled substance. Final rule.
    Drug Enforcement Administration (DEA), Justice.
    Fed Regist; 2007 Sep 24; 72(184):54208-10. PubMed ID: 17912784
    [Abstract] [Full Text] [Related]

  • 11. Opioid drugs in maintenance and detoxification treatment of opiate addiction; Substance Abuse and Mental Health Services Administration, HHS. Final rule.
    Fed Regist; 2001 Jan 17; 66(11):4076-102. PubMed ID: 11503765
    [Abstract] [Full Text] [Related]

  • 12. Schedules of controlled substances: placement of Zopiclone into schedule IV. Final rule.
    Drug Enforcement Administration, Department of Justice.
    Fed Regist; 2005 Apr 04; 70(63):16935-7. PubMed ID: 15806735
    [Abstract] [Full Text] [Related]

  • 13. The ratification of the Convention on Psychotropic Substances 1971 and its transposition into national legislation in the Federal Republic of Germany.
    Schröder O.
    Bull Narc; 1982 Apr 04; 34(3-4):1-19. PubMed ID: 6926511
    [Abstract] [Full Text] [Related]

  • 14. Schedules of controlled substances: rescheduling of the Food and Drug Administration approved product containing synthetic dronabinol [(-) - [DELTA] less than 9 greater than - (trans)-tetrahydrocannabinol] in sesame oil and encapsulated in soft gelatin capsules from schedule II to schedule III. Department of Justice (DOJ), Drug Enforcement Administration (DEA). Final rule.
    Fed Regist; 1999 Jul 02; 64(127):35928-30. PubMed ID: 10558581
    [Abstract] [Full Text] [Related]

  • 15. Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2004 Mar 18; 69(53):12794-7. PubMed ID: 15029891
    [Abstract] [Full Text] [Related]

  • 16. Opioid drugs in maintenance and detoxification treatment of opiate addiction; addition of buprenorphine and buprenorphine combination to list of approved opioid treatment medications. Interim final rule.
    Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services.
    Fed Regist; 2003 May 22; 68(99):27937-9. PubMed ID: 12762334
    [Abstract] [Full Text] [Related]

  • 17. DEA issues proposed rule on e-prescribing.
    Ball FR.
    J Med Pract Manage; 2009 May 22; 24(4):243. PubMed ID: 19288650
    [Abstract] [Full Text] [Related]

  • 18. Preventing the accumulation of surplus controlled substances at long term care facilities. Final rule.
    Drug Enforcement Administration (DEA), Justice.
    Fed Regist; 2005 May 13; 70(92):25462-6. PubMed ID: 15892213
    [Abstract] [Full Text] [Related]

  • 19. Exemption from import/export requirements for personal medical use. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2004 Sep 14; 69(177):55343-7. PubMed ID: 15366181
    [Abstract] [Full Text] [Related]

  • 20. Report of the Expert Advisory Committee on the Use of Drugs in the Treatment of Abuse and Dependence to Narcotic and Controlled Drugs.
    CMAJ; 1990 Nov 01; 143(9):861-5. PubMed ID: 2224712
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.